Skip to content
OpenCapital
Get started

Ardelyx ARDX XPHOZAH — Total revenues

Other product segments

IBSRELA
$70.07M+57.8%
Non-cash royalty revenue related to the sale of future royalties
$695K-32.3%
Product supply revenue
$354K+39.4%
Licensing revenue
$51K-99.0%

Similar metrics at other companies

BioMarin Pharmaceuticals logo
BMRNPALYNZIQ — Total revenues
$89.56M-4.0%
BioMarin Pharmaceuticals logo
BMRNVOXZOGO — Total revenues
$219.88M+2.9%
Bristol-Myers Squibb logo
BMYZeposia — Total Revenues
$118M+10.3%
Bausch + Lomb logo
BLCOPharmaceuticals — Total revenues
$266M+19.8%
HWK
HWKNPharmaceutical — Revenue
$8.32M+15.1%
Cohu logo
COHUPH — Revenue (Gross)
$16.79M+27.3%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%—
Net margin-13.6%—
FCF margin-40.9%—

Returns & leverage

See full
Return on equity-39.5%—
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's xphozah — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's XPHOZAH — total revenues?
Ardelyx (ARDX) reported XPHOZAH — total revenues of $23.3M in Q1 2026.
How has Ardelyx's XPHOZAH — total revenues changed year-over-year?
Ardelyx's XPHOZAH — total revenues decreased by 0.5% year-over-year, from $23.41M to $23.3M.
What does XPHOZAH — total revenues mean?
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeutic asset within a defined reporting period. It reflects the market adoption, pricing strategy, and commercial success of the product in its target patient population. Investors use this to evaluate the revenue contribution and growth trajectory of a key commercialized asset relative to the company's overall portfolio.